BioMark Diagnostics Expands Research Development in Quebec

Vancouver, British Columbia – (August 13th, 2020) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF), a developer of proprietary, non-invasive, and accurate diagnostic solutions announced today that the Company is moving parts of its lung cancer research and development operations to LE CAMP,  an incubator-accelerator dedicated to tech businesses growth and mentorship.


“This move highlights BioMark’s focus on diagnostic development and technological innovation within the healthcare sector,” said Rashid Bux, Chief Executive Officer of BioMark Diagnostics Inc  “The renowned LE CAMP site  offers a diversity of services adapted to similarly sized development stage companies and offers a significant opportunity to form strategic relationships with other industry leaders.  Going forward we intend to invest in human capital and expand our infrastructure in Quebec in order to accelerate the commercialization of our early lung cancer detection platform with IUCPQ (l’Institut universitaire de cardiologie et de pneumologie de Québec) and other excellent strategic partners located across the province. Our institutions have been engaged in clinical studies that have led to very exciting results for potential lung cancer screening.”


BioMark’s research and development is based on the science of metabolomics and leverages Artificial intelligence (AI) systems that make advances in omics and molecular technologies, such as liquid biopsy, faster and more accurate. The Company focuses on the pivotal role that metabolomics plays in early cancer detection with an aim to improve patient treatment outcome. Metabolomics gives you a precise chemical read out on a person’s state of health since it involves the rapid, high throughput characterization of the small molecule metabolites found in an organism.  Additionally, BioMark is targeting a Covid-19 screening, which is focused on fundamentally changing how testing will be done on a global basis.


About Le Camp


A cornerstone of Québec City’s business community, LE CAMP is a vibrant home where ideas flourish and successful businesses are born. LE CAMP is an incubator-accelerator dedicated to growing tech businesses and guiding their creative projects. Located in the Saint-Roch neighborhood in the heart of Québec City, it gives access to acceleration and incubation programs, as well as improvement and networking activities. LE CAMP is managed and led by Québec International, Québec’s metropolitan economic development agency. For more information, please visit

Press Release – BioMark Diagnostics Expands Research Development in Quebec

BioMark’s Affiliated Company, Bio-Stream Diagnostics Inc. Announces Partnership with Qatar University ML Team for Development of COVID-19 Testing

The Company will leverage Raman spectroscopy and Machine Learning as part of its diagnostics


Vancouver, British Columbia – (July 21, 2020) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) announced today that its affiliated company, Bio-Stream Diagnostics Inc.,  will be working with University of Qatar’s Dr. Somaya Al-Maadeed in the development of its novel COVID-19-detection method, leveraging new generation Raman spectroscopy and the power of machine learning. Raman spectroscopy is a spectroscopic technique typically used to determine vibrational modes of molecules, although rotational and other low-frequency modes of systems may also be observed. Raman spectroscopy is commonly used in chemistry to provide a structural fingerprint by which molecules can be identified.


Professor Al- Maadeed heads the Computer Science and Engineering Department at Qatar University with research interests in Pattern Recognition, Image and Signal Processing, AI, Bio-Metrics, Character Recognition, Writer Identification, and Digital Library. Prof Al-Maadeed is a recent recipient of a grant from Qatar University’s Predicting Risk Early in COVID-19 -The PERIL Study which fits very well with Bio- Stream’s research and future commercialization objectives.


“We are delighted to have Professor Al- Maadeed and her dedicated group from Qatar University to be part of our research team with a special focus on the use of ML in rapid COVID -19 diagnosis,” said Mr. Rashid A. Bux, President & CEO of BioMark Diagnostics, Inc.  “The additional ML resources and talent that both Professor Al-Maadeed and Qatar University provide will complement our already strong ML group. This collaboration demonstrates our global intent to partner with leading institutions and organizations that are seeking ways to bringing in rapid, effective and economical COVID -19 screening solutions to market.”


About Qatar University

Since its inception in 1977, Qatar University (QU) continues to serve as Qatar’s primary institution of higher education and has become today a beacon of academic and research excellence in the region.  QU hosts ten colleges — College of Arts and Sciences (CAS), College of Business and Economics (CBE), College of Education (CED), College of Engineering (CENG), College of Health Sciences (CHS), College of Law (LAWC), College of Medicine (CMED), College of Pharmacy (CPH), College of Sharia and Islamic Studies (CSIS) and College of Dental Medicine (CDM).  Research is an integral part of the academic environment at QU and is bolstered by the state-of-the-art Research Complex, and 14 research centers of excellence. It is further enhanced by over 400 collaborative projects in over 130 countries.

Community engagement is an area stationed at the heart of QU’s mission and vision. The University prides itself on the quality of its students and alumni and is committed to ensuring that campus life is an enriching environment for encouraging academic excellence, volunteerism, civic responsibility, and leadership.  QU is advancing its goal to become a leader of economic and social development in Qatar through collaborations and partnerships with industry, government, academia, business, and civil society in Qatar and beyond.


Press Release – BioStream Diagnostics Inc. Collaborates with Qatar University

BioMark Diagnostics Inc. Receives Full Registered Trademark Status from the US Patent and Trademark Office for its Company Brand Name “BioMark”

Vancouver, British Columbia – (July 16, 2020) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) announced today that the Company has been granted a Full Registered Trademark Status from the US Patent and Trademark Office for its Company Brand Name “BioMark”.  The term “BioMark” was selected by the company in reference to their Biomarker Testing capabilities in the fields of cancer treatment and anti-cancer preparations.


Biomarker testing is comprised of a group of tests that looks for specific molecular signs (or signatures) related to cancer so that doctors can plan the best cancer treatment care. In addition, the trademark can also be used for claiming preparation of anti-cancer properties.


“We believe that this trademark significantly enhances our brand while clearly communicating our mission and proficiency in leveraging novel biomarker testing methods for cancer treatment and development of anti-cancer preparation,” said Rashid Bux, Chief Executive Officer of BioMark Diagnostics Inc.  “Going forward, this trademark will provide us with an additional layer of name recognition with investors, potential bio-technology partners and members of the scientific community. This is an opportune time to receive the trademark as we strive to accelerate commercialization of our assays and to establish ourselves as a market leader in the rapidly growing cancer medical testing, treatment and anti-cancer preparation sector.”

Press Release – BioMark Diagnostics Inc. Receives Full Registered Trademark Status from the US Patent and Trademark Office

BioMark Diagnostics Announces Peer Reviewed Publication on Detection of Cancer

Vancouver, British Columbia – (June 23 , 2020) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF), a developer of proprietary, non-invasive, and accurate cancer diagnostic solutions to assist in detecting, monitoring and assessing treatment for cancer early and cost effectively, announced today a peer reviewed scientific publication to support its innovative cancer diagnostic platform that repurposes a U.S. Food and Drug Administration (FDA) off patent drug for a new application.


BioMark’s team recently published an article titled “Versatility of Amantadine and Rimantadine for Detection of Cancer” in Novel Advances in Cancer with citation: Bram Ramjiawan, Andrew W Maksymiuk, Rashid Ahmed Bux, Tappia Paramjit S, et al. Versatility of Amantadine and Rimantadine for Detection of Cancer. Nov Appro in Can Study. 4(4). NACS.000591. 2020. DOI: 10.31031/NACS.2020.04.000591.


The article is posted on BioMark’s website:


“The publication further demonstrates the versatility of BioMark’s SSAT cancer diagnostic platform that uses FDA approved agents and measures with urinary or plasma concentration of the acetylated substrates utilizing our proprietary validated internal laboratory standards,” says Rashid Bux, CEO of BioMark Diagnostics.  “Our test has multiple clinical applications addressing the most critical issues associated with the disease.  BioMark’s platform can detect and diagnose the presence of cancer, determining an individual’s risk of developing cancer, monitoring response to treatment, and the possible measurement of recurrence for cancer survivors.  I believe that this announcement further validates our commitment to investing in science while building and protecting its core cancer technology platform.”

Press Release – BioMark Diagnostics Announces Peer Reviewed Publication on Detection of Cancer